Video Experimental Relacionado
Updated: Jun 19, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
342
Transformar la obesidad: el avance de los fármacos con múltiples receptores
Christine M Kusminski1, Diego Perez-Tilve2, Timo D Müller3
1Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|July 26, 2024
Resumen
Los nuevos poligonistas de hormonas intestinales dirigidos a los receptores de péptido tipo glucagón-1 (GLP-1) ofrecen una reducción significativa del peso, hasta un 30%. Estos medicamentos avanzados contra la obesidad son prometedores como una alternativa farmacológica a la cirugía.
Área de la Ciencia:
- Farmacología
- Endocrinología
- Enfermedades metabólicas
Sus antecedentes:
- Los médicos han buscado durante mucho tiempo métodos farmacológicos para reducir el exceso de grasa corporal.
- Los avances recientes en la ingeniería bioquímica han llevado a nuevos agentes terapéuticos para el control de la obesidad.
Objetivo del estudio:
- Revisar el desarrollo y la eficacia de los poliagonistas basados en GLP-1 para la reducción de peso.
- Para resaltar los beneficios multifacéticos de estos nuevos medicamentos contra la obesidad.
Principales métodos:
- Revisión de la literatura científica reciente sobre los agonistas y poliagonistas de los receptores GLP-1.
- Análisis de los mecanismos farmacológicos subyacentes a la reducción de peso y los beneficios para la salud asociados.
Principales resultados:
- Los poliagonistas basados en GLP-1, que incorporan receptores de glucagón y/o GIP, logran una reducción sustancial del peso (hasta un 20%-30%).
- Estos agentes demuestran efectos favorables sobre la glucemia, la enfermedad hepática grasa, la enfermedad renal, la salud cardiovascular y el tejido adiposo.
Conclusiones:
- Los poligonistas de hormonas intestinales representan un avance significativo en la farmacoterapia contra la obesidad.
- Estas nuevas intervenciones ofrecen una alternativa farmacológica prometedora a la cirugía bariátrica para controlar la obesidad y las comorbilidades relacionadas.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
01:15G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
01:25Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K